Lilly’s Lartruvo get EU nod for soft tissue sarcoma
Eli Lilly’s Lartruvo has received a conditional marketing approval by the European Commission to treat soft tissue sarcoma (STS).
Read More
Tag: Latruvo
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
- Incyte treatment for advanced anal cancer approved in Europe
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
